Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 1 7 Monireh Asadi Hematology– Oncology and Stem Cell Research Center, Shariati Hospital, Tehran University of Medical Sciences, & Islamic Azad University,Tehran Medical Branch, School Of Paramedicine, Tehran, Iran Arpi Manookian Ph.D Student, Tehran University of Medical Sciences, School of Nursing & Midwifery, Tehran, Iran Alireza Nikbakht Nasrabadi Associate Professor, Tehran University of Medical Sciences, School of Nursing & Midwifery, Tehran, Iran 2015 10 01 Introduction: It is an unfamiliar, frightening and stressful experience for the parents of a child who is undergoing bone marrow transplantation. It is impossible to propose an effective caring method without considering all dimensions related to such experience. Objective: The purpose of this study was to describe and understand the lived experiences of parents whose children were undergoing bone marrow transplantation process. Methods: This research was a phenomenological study in which parents of 6 children with bone marrow transplantation were participated. Data collection method was semi- structured and profound, in-depth, face to face interviews. Data then were analyzed using interpretative phenomenological approach. Results: Four major themes emerged from the data: 1) pending between dread and hope of the transplantation result, 2) exalting spirituality, 3) worry about circumstantial difficulties, and finally 4) life lessons learned. Conclusion: During bone marrow transplantation process, parents of the children who undergoing transplantation, are experiencing a lot of problems, affections, difficulties, dreads, tensions, emotional conflictions and at the same time they learn a lot. Implications for Practice: It should be acknowledged for nurses to be more sensitive to pay attention to parents' needs during their children bone marrow transplantation. Nurses need to recognize the power of spiritual factors which may help parents in coping with circumstantial difficulties of the bone marrow transplantation. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/264 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/264/257

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 8 10 Kamran Alimoghaddam Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Mohamad Jahani Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Arash Jalali Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Hoda Jorjani Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Massoud Iravani Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Amir Ali Hamidieh Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Asadolah Mousavi Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Babak Bahar Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Maryam Behfar Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Roshanak Derakhshandeh Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran Shahrbanoo Rostami Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Acute promyelocytic leukemia treatment revolutionized by new tretaMNETS. Currently number of patinets who undergoe hematopoietic stem cell transplantation decrased so experience with this modality is limited. Here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients. Design and setting: retrospective, single center Methods: between year 2000 and 2011 we performed 20 HSCT in APL. Median age of patients was 25 year old. Patients received 3 autologous and 17 allogeneic HSCT from their HLA full match sibling donor. Different type of conditioning regimens applied for them. We used Cyclosporine and Methotraxtae as prophylaxis of GVHD after allogeneic HSCT. Results: Hematopoietic stem cell engraftment observed in all cases. Acute GVHD was mild to moderate in all except one and was manageable.one patient dies due to aGVHD. Chronic GVHD was extensive in 2 cases and one mortality observed due to sever cGVHD. Mortality rate was 35% with a median follow up of 3.5 years. Five patinets died due to their primary disease relapse after HSCT. Three years DFS and OS were 63.1 and 77.2% respectively. Conclusion: hematopoietic stem cell transplantation is an acceptable consolidation for APL. Choosing between autologous or allogeneic transplantation, need facilities such as reliable method for molecular remission detection before HSCT and also close and reliable follow up of patients with clinical and molecular parameters. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/265 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/265/258

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 11 15 Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Roshanak Derakhshandeh Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Arash Jalali Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ali Jafarpour Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran AmirAli Hamidieh Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Babak Bahar Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Masoud Iravani Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Seied Asadollah Mousavi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammad Jahani Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introductio: Hematopoietic stem cell transplants (HSCT) are considered as treatment options for patients with solid tumors. Transplant numbers have changed significantly over the last decade. We have done Autologous and Allogeneic HSCT for treatment of solid tumor patients in our center. Methods: In order to show the transplant effect on solid tumor treatment, we collected data from 71 patients (7 allogeneic, and 64 autologous) who had undergone HSCT from 1991 to 2011 in our center. The median age of patients was 19.5 years (range: 2-58). The Male/Female ratio was 41/30. The most common transplant diseases were Neuroblastoma (18, 25.7%), Germ Cell Tumors (13, 18.6%) and Breast Cancer (11, 15.7%). 67 patients (95.7%) received peripheral blood and the 3 other ones (4.3%) received bone marrow as a source of SCT. Results: The median time of hospitalization after high-dose therapy was 24 days (range: 11-50 days; 23 days for autologous and 29 days for allogeneic patients). At present, 57 patients (80%) are still alive with median follow-up of 9 months. Transplant-related mortality (TRM) was 4.3%. The causes of death were progressive disease, metastasis and multi-organ failure. 2-year overall and disease-free survivals were 81.7% and 72%, respectively (for the autologous patients overall and disease-free survivals were 80.7% and 71.1%, respectively). Among 7 patients with allogeneic transplantation, 2 developed acute-graft-versus host disease (GVHD) and 4 developed chronic GVHD. One patient had chronic GVHD following acute GVHD. Conclusion: Our study reveals promising results of HSCT in the treatment of some solid tumors. In other hand, more additional trial study is needed. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/266 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/266/259

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 16 19 Mohammad ali Mashhadi Hematology- Oncology Department, Zahedan University of Medical Sciences, Zahedan, Iran Mohammd Mahammadi Health promotin research center, Zahedan University of Medical Sciences, Zahedan, Iran Alireza Bakhshipour Gastroentrology Department, Zahedan University of Medical Sciences, Zahedan, Iran Mahmoudali Keikhaei Endocrinology Department, Zahedan University of Medical Sciences, Zahedan, Iran Mahnaz Sandoughi Rheumatology Department, Zahedan University of Medical Sciences, Zahedan, Iran Zahra Heidari Endocrinology Department, Zahedan University of Medical Sciences, Zahedan, Iran Hooshang Sanadgol Nephrology Department, Zahedan University of Medical Sciences, Zahedan, Iran Amin Mashhadi School of Medicine Student, Zahedan University of Medical Sciences, Zahedan, Iran 2015 10 01 Introduction: Methotrexate (MTX) is an anti folate drug that used in malignant and non malignant patients. The usage of high dose methotrexate was limited to patients with: Osteogenic sarcoma, Ewing sarcoma and Lymphoma. The aim this study was to determine the toxicity or side effects of very high dose methotrexate (8-10 gr/m2/cycle). This study is the first study in Iranian patients and one of few study in world wide with this dosage and number of patients. Patients and methods: In a prospective study on all patients with osteogenic sarcoma, Ewing sarcoma , and lymphoma that candidate for high dose MTX (mean total dosage was 27 gr/m2/case without any underlying disease, and after full physical examination and performing necessary paraclinical tests (Na, K, BUN, Cr, Uric acid, AST, ALT, Bilirubin, and ECG entered and information was filled for all of them prior and after the every cycle. The follow up visit include: repeated physical examination and duration of its was at least 6 months. Results: There were 102 cases, 60 cases were male (58.8%), 42 female (41.2%), median age was 19.5 (5-80), Osteogenic sarcoma and Ewing sarcoma 87 cases (49/male and 38/female), 15 cases were Lymphoma (11/male, 4/female). Total course of MTX therapy was 273 (median courses were 2.67/patient). Our result revealed: Abdominal pain due to hepatomrgally was not obsereved, rising in bilirubin and alkaline phosphetase were not observed, but rising in AST and ALT were the most common liver toxicity due to high dose MTX and detail were: this toxicity was in 23 cases (46.9%) [11/men (18.3%) and 12/female (28.6%)] respectively. The maximum toxicity was grade 2 toxicity according to NCI criteria. All of them resolved spontaneously without any specific management and treatment except watch and wait. Conclusion: This study revealed that the usage of very high dose methotrexate had liver toxicity but these toxicities were limited to abnormal AST and ALT. All of these toxicities were transient and resolved without any scar on liver function after cessation of therapy. After at least 6 months follow up we didn’t see any abnormality. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/267 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/267/260

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 20 29 Mohsen Nikbakht Department. of Biotechnology, Panjab University (PU), Chandigarh, India. AND Department of experimental medicine and Biotechnology, Post Graduate Institute of Medical Education Abhimanyu Jha Department. of Biotechnology, Panjab University (PU), Chandigarh, India Kianoosh MalekZadeh Molecular Medicine Research Center: Medical University of Hormozgan, Bandar Abbas, Iran Marjan Askari Department. of Biotechnology, Panjab University (PU), Chandigarh, India Neena Capalash Department. of Biotechnology, Panjab University (PU), Chandigarh, India Marwaha Ram Kumar Advanced Pediatric Center, Post Graduate Institute of Medical Education and Research, Chandigarh Deepak Kaul Department of experimental medicine and Biotechnology, Post Graduate Institute of Medical Education Jagdeep Kaur Department. of Biotechnology, Panjab University (PU), Chandigarh, India 2015 10 01 Introduction: Acute Lymphoblastic Leukemia (ALL) is the most worldwide common type of childhood cancer. Methylenetetrahydrofolate reductase (MTHFR) and 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) are crucial enzymes in folate pathways. Folate availability is critical factor for DNA integrity, required for the transfer of methyl group in the biosynthesis of thymidilate. Procedure: In present study, we have conducted a case control study from north Indian states  to correlate the effect of two SNPs of MTHFR (677C→T and 1298A→C) and MTR (2756A→G) and the risk of childhood ALL. One hundred and twenty five bone marrows and peripheral blood samples and 100 sex-age matched healthy controls were obtained and analyzed by PCR-RFLP method. Results: Statistically, no significant differences were observed between patients and controls for different genotypes (p>0.05), also significant different on risk of ALL in individuals having genotype of MTHFR 677TT (OR=0.61, 95% CI=0.21-1.77) and MTHFR 1298CC (OR=0.56, 95% CI=0.18-1.68) was not observed. Statistically, the correlation of variants of MTR gene and risk of ALL was not observed. Conclusions:The difference in distribution of possible combined genotypes of MTHFR (677C→T, 1298A→C) and MTR (2756A→G) between patients and controls were statistically insignificant. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/268 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/268/261

Tehran University of Medical Sciences 26 33 Marjan Yaghmaie Medical Genetics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Hossein Mozdarani Medical Genetics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Kamran Alimoghaddam Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University, Tehran, Iran Ardeshir Ghavamzadeh Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University, Tehran, Iran Seyed Hamiollah Ghaffari Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University, Tehran, Iran 2015 10 01 Introduction: The secondary genetic changes other than the PML-RARA fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established. Patients & Methods: FLT3 ITD screening by fragment length analysis and FLT3 D835 mutation by melting curve analysis in 23 APL samples was screened in this study. Results: About13% of the patients had FLT3 internal tandem duplications (ITDs), and 26% had D835 point mutation. FLT3 ITD mutation was associated with higher white blood cell (WBC) count at presentation and poor prognosis. Conclusions: As the PML-RARA is not sufficient to develop APL, we assume FLT3 mutations and additional chromosomal alterations in this APL series may cooperate with PML-RARA in APL development. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/253 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/253/246

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 4 3 2010 09 15 36 39 Gholamreza Toogeh Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran Reza Shirkoohi Molecular Genetics, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran, Iran Manouchehr keyhani Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran Mehdi Nickbin Department of Infectious Diseases, Pasargad Hospital, Tehran, Iran Safa Najafi Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran Maryam Salimi Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran Leila Farsi Physiology Department, Basic Sciences Ward, Gonabad University of Medical Sciences, Gonabad, Iran Shirin Ferdowsi Hematology Department, Basic Sciences Ward, Gonabad University of Medical Sciences, Gonabad, Iran 2015 10 01 We describe a case of leishmaniasis in a 55-year-old male who presented with weakness, fever and anemia. The patient was born and lived all his life in Talaghan, a non-endemic region of kala-azar and there was no history of travel to endemic reigon for leishmania. In primary diagnosis, the patient suspect has been myelofibrosis and then lymphoma and underwent chemotherapy. His general condition worsened and bone marrow biopsy was performed again and leishmania promastigotes seen in the bone marrow. Specific identification of the parasite was done by RAPD-PCR. After two weeks of treatment, he was transferred to ICU due to heart attack and after 4 days he died due to aortic valve ABE. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/254 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/254/247

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 4 3 2010 09 15 40 42 Mohammadali Mashhadi Hematology-Oncology Department, Ali-e- ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran 2015 10 01 The hematological malignancies associated with nephrotic syndrome are mainly hodgkin’s and non-hodgkin’s lymphomas and chronic lymphocytic leukemia. Acute myelogenous leukemia (AML) has rarely been described in associated with nephritic syndrome. We report a rare case of acute myelogenous leukemia who presented with nephrotic syndrome. A previously healthy 62-year-old man was admitted in nephrology ward because of generalized developing pitting edema during last month. Simultaneously, he had generalized itching and urticaria, polyuria, polydypsia and low grade fever but had no history of weight loss, anorexia and sweating. In laboratory tests he had pr